MYC and lymphoma: Of note, the single expression of MYC is present in 25% to 30% of lymphoma, irrespective of COO, and does not represent an adverse prognostic factor in patients treated with R-CHOP.23 In contrast, BCL2 overexpression is highly correlated with ABC subgroup, and in some series has been associated with inferior PFS, independently from international prognostic index (IPI) and COO.24